Cell-based Cancer Immunotherapy

Erscheinungsjahr 2024
ISBN: 978-0-443-13995-6
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 191 mm x 235 mm, Gewicht: 450 g

Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinical aspects. Topics covered in this volume include Methods behind clinical DC vaccine products against glioblastoma, Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy, Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients, Identification of TCR repertoire patterns linked with anti-cancer immunotherapy, Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells, Methods behind neoantigen predictions for anticancer vaccines, Methods behind CD137L-DC-EBV-VAX anticancer vaccine, and much more.

Additional sections cover Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies, Methods behind TCR analyses for colorectal cancer-associated TILs, The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays, Humanized mouse models for anti-cancer therapy, In vitro re-challenge of CAR T cells, Methods behind adoptively transferred tumor draining lymphocytes? for anticancer immunotherapy, and A murine glioblastoma platform to test cellular therapies with the standard of care.

Autoren/Hrsg.

Weitere Mitwirkende

Garg, Abhishek

Fachgebiete

• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Biowissenschaften Entwicklungsbiologie
• Naturwissenschaften Biowissenschaften Zellbiologie

Inhaltsverzeichnis

1. Methods behind clinical DC vaccine products against glioblastoma
Rüdiger V. Sorg
2. Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy
Jolanda de Vries and Gerty Schreibelt
3. Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Stefaan W. Van Gool
4. Identification of TCR repertoire patterns linked with anti-cancer immunotherapy
Kris Laukens and Romi Vandoren
5. Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells
Eva Lion and Kris Laukens
6. Methods behind neoantigen predictions for anticancer vaccines
Cedric Bogaert
7. Methods behind CD137L-DC-EBV-VAX anticancer vaccine
Herbert Schwarz
8. Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies
Dmitri Krysko
9. Methods behind TCR analyses for colorectal cancer-associated TILs
Sara Verbandt, Ting Pu and Sabine Tejpar
10. The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays
Adam Snook
11. Humanized mouse models for anti-cancer therapy
Eleonora Leucci
12. In vitro re-challenge of CAR T cells
Sebastien Walchli and Alicia Villatoro
13. Methods behind adoptively transferred tumor draining lymphocytes? for anticancer immunotherapy
Harry D. Bear and Carolyn Haynes
14. A murine glioblastoma platform to test cellular therapies with the standard of care
An Coosemans and Aaron Ziani Zeryouh Jr.

Über Autor(innen)

Garg, Abhishek
Prof. Abhishek D. Garg is currently Assistant Professor at Department of Cellular & Molecular Medicine (KU Leuven, Belgium) and head of the Laboratory for Cell Stress & Immunity also at KU Leuven. Dr. Garg did his post-doctoral training at KU Leuven, combined with research visitations at University of Helsinki, Finland, and De Duve Institute, Belgium, after receiving his PhD from KU Leuven. During his PhD-postdoc stints, Dr. Garg played an instrumental role in elucidating novel mechanisms that make cancer cell death immunogenic in the context of anticancer therapy. He worked on uncovering the links between endoplasmic reticulum stress, autophagy, apoptosis/necroptosis, and damage-associated molecular patterns (DAMPs) or danger signals in dying cancer cells. This work resulted in creation of innovative dendritic cell (DC) vaccines against glioblastoma.

His lab focuses on applying novel reverse translational approaches (i.e. human data to pre-clinical validation) to create innovative immunotherapy or biomarker solutions against hard-to-treat immunotherapy resistant tumors and eventually pave way for the forward translation of these solutions toward the clinic. His lab is working closely with oncologists (at home & abroad) for translation toward early-stage clinical trials.

His >100 publications have been cited >20,000 times (h-index >50). He has delivered >40 lectures at various (inter)national conferences or institutional/company seminars. Dr. Garg's contributions have been recognized by the 41st Prix Galien award for Pharmacological Research (Belgium, 2023), KU Leuven Research Council Award (2016), European Society of Photobiology (ESP) Young Investigator Award (2013), and FWO-McKinsey & Company Scientific Prize (2012).